Novamigra Therapeutics is an innovative pharmaceutical company spun out of VRG Therapeutics and focused on developing next-generation preventive treatments for migraine. Its lead compound, VRG-145, is aimed at patients who fail to respond adequately to existing options such as antiepileptics, beta-blockers, antidepressants, calcium-channel blockers, and CGRP-targeting drugs. Over the past year the company has aligned its clinical strategy with both the U.S. FDA and Hungary’s NNGYK, finalized the design of a 36-volunteer Phase 1 pharmacokinetic and safety study, and completed key CMC pre-formulation work. Novamigra has also reinforced its intellectual-property position with patents published by the EPO and USPTO and an additional priority filing in the United States. To date, the company has raised roughly €5 million, including about €2 million in non-dilutive grants from Hungary’s NKFIH and the newly secured ~€3 million financing round. Management is actively exploring strategic co-development and commercialization partnerships with European pharmaceutical companies as VRG-145 moves toward first-in-human testing.

Total raised

$4M

Funding rounds

1

Latest round

Equity

Latest activity

Jan 2026